Correspondence 0000950103-23-014246 from NOVO NORDISK A S (NVO, NONOF) (CIK 0000353278) (NVO)

NOVO NORDISK A S (NVO, NONOF) (CIK 0000353278)
Date: Sept. 29, 2023 · CIK: 0000353278 · Accession: 0000950103-23-014246

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-82318

Referenced dates: September 27, 2023

Date

September 29, 2023

Author

/s/ Leo Borchardt

Form

CORRESP

Company

NOVO NORDISK A S (NVO, NONOF) (CIK 0000353278)

Letter

Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549

Dear Ms. Majmudar and Ms. Dorin:

I am writing on behalf of Novo Nordisk A/S (the “Company”) in connection with the Staff’s review of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2022. I confirm that the Company has received and is considering its response to your letter dated September 27, 2023.

In order to ensure the completeness and accuracy of the Company’s response, it will be conducting a detailed review of the items concerned in respect of the above filing.

The Company anticipates being able to complete this review and provide a response to the SEC by no later than Friday, October 20, 2023.

Very truly yours,
/s/ Leo Borchardt

Show Raw Text

CORRESP
1
filename1.htm

    Leo Borchardt

    +44 20 7418 1334

    leo.borchardt@davispolk.com

    Davis Polk & Wardwell
    London llp

    5 Aldermanbury Square

    London EC2V 7HR

    davispolk.com

    September 29, 2023

    Re:
    Novo Nordisk A/S

Form 20-F for the Fiscal Year Ended December 31, 2022

Filed February 1, 2023

File Number:  333-82318

Anuja A. Majmudar

Karina Dorin

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Dear Ms. Majmudar and Ms. Dorin:

I am writing on behalf of Novo Nordisk A/S (the “Company”)
in connection with the Staff’s review of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2022.
I confirm that the Company has received and is considering its response to your letter dated September 27, 2023.

In order to ensure the completeness and accuracy of the Company’s
response, it will be conducting a detailed review of the items concerned in respect of the above filing.

The Company anticipates being able to complete this review and provide
a response to the SEC by no later than Friday, October 20, 2023.

Very truly yours,

/s/ Leo Borchardt

Leo Borchardt

 cc: Karsten Munk Knudsen
 Novo Nordisk A/S

Via Edgar Submission

SecProbe.io